Successful Treatment With Direct-Acting Antiviral Agents of Hepatitis C in Patients With End-Stage Renal Disease and Kidney Transplant Recipients

dc.contributor.authorEtik, Digdem Ozer
dc.contributor.authorSuna, Nuretdin
dc.contributor.authorOcal, Serkan
dc.contributor.authorSelcuk, Haldun
dc.contributor.authorDagli, Ulku
dc.contributor.authorColak, Turan
dc.contributor.authorHilmioglu, Fatih
dc.contributor.authorBoyacioglu, Ahmet Sedat
dc.contributor.authorHaberal, Mehmet
dc.contributor.orcID0000-0003-3719-9482en_US
dc.contributor.orcID0000-0003-0664-0976en_US
dc.contributor.orcID0000-0002-9370-1126en_US
dc.contributor.pubmedID30719954en_US
dc.contributor.researcherIDABH-4817-2020en_US
dc.contributor.researcherIDAAE-7637-2021en_US
dc.contributor.researcherIDS-4068-2018en_US
dc.date.accessioned2021-02-24T09:52:13Z
dc.date.available2021-02-24T09:52:13Z
dc.date.issued2019
dc.description.abstractObjectives: The introduction of direct-acting antiviral agents has allowed significant chances for treatment for difficult-to-treat populations. This study aimed to investigate the efficacy, tolerability, and safety of these therapies in both patients with end-stage renal disease and kidney transplant recipients with chronic hepatitis C virus infection. Materials and Methods: This study was a retrospective analysis with prospective follow-up of patients. The antiviral combination of ombitasvir 25 mg, paritaprevir 75 mg, ritonavir 50 mg, and dasabuvir 50 mg was prescribed to patients with end-stage renal disease or kidney transplant recipients with noncirrhotic or compensated cirrhotic liver disease. The other antiviral combination consisted of sofosbuvir 400 mg and ledipasvir 90 mg, which was recommended to patients with decompensated cirrhosis or those who could not tolerate the first combination regimen. Ribavirin was given to all patients with genotype 1a hepatitis C virus infection. All clinical and laboratory data were recorded at week 4, at end of the treatment, and at 12 weeks after completion of treatment. Results: In terms of efficacy, sustained virologic response at 12 weeks was achieved in 94% of patients in the end-stage renal disease group and 92% of patients in the kidney transplant group. In terms of tolerability, antiviral treatment was well tolerated in both groups. Cardiac arrest and cerebrovascular accident were seen in the end-stage renal disease group; severe mucositis and glossitis were seen in the kidney transplant group. Hospitalization was needed in 2 patients for treatment of drug interactions with tacrolimus and sirolimus. Renal allograft function worsened in 2 patients, with 1 patient having biopsyproven antibody-mediated rejection. Conclusions: We observed great efficacy and safety in both kidney transplant recipients and patients with end-stage renal disease with these agents in treatment of chronic hepatitis C. However, clinicians should remain aware of drug interactions and adverse events in this fragile patient population.en_US
dc.identifier.endpage58en_US
dc.identifier.issn1304-0855en_US
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85061151653en_US
dc.identifier.startpage52en_US
dc.identifier.urihttp://hdl.handle.net/11727/5388
dc.identifier.volume17en_US
dc.identifier.wos000462169400010en_US
dc.language.isoengen_US
dc.relation.isversionof10.6002/ect.2018.0095en_US
dc.relation.journalEXPERIMENTAL AND CLINICAL TRANSPLANTATIONen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectImmunosuppressive medicationen_US
dc.subjectRenal transplanten_US
dc.subjectSustained virologic responseen_US
dc.titleSuccessful Treatment With Direct-Acting Antiviral Agents of Hepatitis C in Patients With End-Stage Renal Disease and Kidney Transplant Recipientsen_US
dc.typearticleen_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: